The treatment of adolescents and young adults with acute lymphoblastic leukemia

References

• Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144:147–156.
   PubMed Web of Science ®Google Scholar
• Harrison CJ. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood. 2015;125:1383–1386.
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–615.
   PubMed Web of Science ®Google Scholar
• Den Boer ML, van Sleglenhorst M, de Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–134.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, et al. Children’s oncology group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–486.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating fusions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–1015.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Am Soc Hematol Edu Book. 2005;2005:123–130.
   Google Scholar
• Jain N, Lamb AV, OBrien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP ALL/LBL) in adolescents and young adults: a high risk subtype. Blood. 2016;127:1863–1869.
   PubMed Web of Science ®Google Scholar
• Wood BL, Winter SS, Dunsmore KP, et al. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in children: children’s oncology group (COG) study AALL0434. Blood. 2014;124:1.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774–780.
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646–1654.
   PubMed Web of Science ®Google Scholar
• Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012;87:472–478.
   PubMed Web of Science ®Google Scholar
• Stock W, Luger S, Advani A, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133:1548–1559.
   PubMed Web of Science ®Google Scholar
• Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk acute lymphoblastic leukemia: a report from Children’s Oncology Group study AALL0232. JCO. 2016;34:2380–2388.
   PubMed Web of Science ®Google Scholar
• Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children’s oncology group. JCO. 2009;27:5189–5194.
   PubMed Web of Science ®Google Scholar
• Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017;102:2086–2096.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study. J Clin Oncol. 2019;37:1638–1646.
   PubMed Web of Science ®Google Scholar
• Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyperCVAD regimen. Am J Hematol. 2016;91:819–823.
   PubMed Web of Science ®Google Scholar
• Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;127:833–841.
   Google Scholar
• Kozlowski P, Astrom M, Ahlberg L, et al. Swedish adult ALL group. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with hyper-CVAD chemotherapy in Sweden. Eur J Haematol. 2014;92:377–381.
   PubMed Web of Science ®Google Scholar
• Dunsmore KP, Winter S, Devidas M, et al. COGAALL0434: a randomized trial testing nelarabine in newly diagnosed T-cell malignancy. JCO. 2018;36:10500.
   Web of Science ®Google Scholar
• Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. JCO. 2010;28:3880–3889.
   PubMed Web of Science ®Google Scholar
• Hoezler D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev. 2012;26:25–32.
   PubMed Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044–1053.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474–2487.
   PubMed Web of Science ®Google Scholar
• Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;pii: S1083–8791:30267–30268.
   Google Scholar
• Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317:1255–1260.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Combret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–1531.
   PubMed Web of Science ®Google Scholar
• Alford SE, Kothari A, Loeff FC, et al. BH3 inhibitor sensitivity and bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75:1366–1375.
   PubMed Web of Science ®Google Scholar
• Alexander T, Lacayo N, Pullarkat VA, et al. Venetoclax and navitoclax in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 2018;132:3966.
   Web of Science ®Google Scholar
• Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995–999.
   PubMed Web of Science ®Google Scholar
• Manesh M, El-Hoss J, Evans K, et al. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood. 2015;126:1193–1202.
   PubMed Web of Science ®Google Scholar
• Medd PG, Peniket AJ, Littlewood TJ, et al. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British society of blood and marrow transplantation study. Bone Marrow Transplant. 2013;48:982–987.
   PubMedGoogle Scholar
• Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the american society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21:1863–1869.
   PubMed Web of Science ®Google Scholar
• Carreras E, Dufour C, Mohty M, et al, editors. The EBMT Handbook. Hematopoietic stem cell transplantation and cellular therapies. Cham: Springer;2019.
   Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–1833.
   PubMed Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463–471.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–4162.
   PubMed Web of Science ®Google Scholar
• Campana D, Leung W. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol. 2013;162:147–161.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.
   PubMed Web of Science ®Google Scholar
• Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486–2496.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Children's oncology. long-term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031. Leukemia. 2014;28:1467–1471.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Saha V, Devidas M, et al. CA180-372: an international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL). Blood. 2017;130:98–98.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122:3650–3656.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Othus M, O'Brien SM, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in philadelphia chromosome positive ALL. Blood Adv. 2016;1:250–259.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–1518.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. . 2015; 7:303ra139.
   PubMed Web of Science ®Google Scholar
• Lee DW, Stetler-Stevenson M, Yuan CM, et al. Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. Blood. 2016;128:218–218.
   Web of Science ®Google Scholar
• Park JH, Riviere I, Wang X, et al. Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy. JCO. 2017;35:7008–7008.
   Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–385.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–638.
   PubMed Web of Science ®Google Scholar
• Graham C, Jozwik A, Pepper A, et al. Allogeneic CAR-T cells: more than ease of access? Cells. 2018;7:155.
   PubMed Web of Science ®Google Scholar
• Shalabi H, Shah NN, Fry TJ, et al. Intensification of lymphodepletion optimizes CAR Re-treatment efficacy. Blood. 2017;130:3889.
   Web of Science ®Google Scholar
• Gardner R, Finney O, Brakke H, et al. Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy. Blood. 2018;132:4022.
   Web of Science ®Google Scholar
• Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–3331.
   PubMed Web of Science ®Google Scholar